NeuroSense Therapeutics annual capital expenditures (capex)
2019
2020
2021
2022
2023
2024
2025
NeuroSense Therapeutics Capital Expenditures (CapEx) Growth & History (NRSN)
NeuroSense Therapeutics's capital expenditures (capex) was $8,000 for fiscal 2025.
View full NeuroSense Therapeutics company overviewNeuroSense Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8,000 | $5,000 | +166.67% |
| 2024 | 2024-12-31 | $3,000 | −$26,000 | −89.66% |
| 2023 | 2023-12-31 | $29,000 | −$41,000 | −58.57% |
| 2022 | 2022-12-31 | $70,000 | $53,000 | +311.76% |
| 2021 | 2021-12-31 | $17,000 | $8,000 | +88.89% |
| 2020 | 2020-12-31 | $9,000 | $2,000 | +28.57% |
| 2019 | 2019-12-31 | $7,000 | — | — |
NeuroSense Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, NeuroSense Therapeutics's capital expenditures (capex) decreased from $9,000 to $8,000, a change of −$1,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NeuroSense Therapeutics source filings ↗